Clinical and imaging findings, treatments, and outcomes in 27 dogs with imaging diagnosed trigeminal nerve sheath tumors: A multi‐center study

Swift, Katie E.; McGrath, Stephanie; Nolan, Michael W.; Young, Martin; Reese, Michael J.; Rao, Sangeeta; Randall, Elissa; Leary, Del; LaRue, Susan M.

doi:10.1111/vru.12535

Cited by 25 publications

(35 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 The mean dose to 1 cc of normal brain for the patients that received 4 fractions of SRT was 22.6Gy (range, [19][20][21][22][23][24][25][26][27][28]. The mean dose to 1 cc of normal brain for the patients that received 3 fractions of SRT was 19.5Gy (range, [16][17][18][19][20][21][22][23][24]. The dose to 1 cc of normal brain for the patient that received a single fraction of 17Gy was 9.0Gy.…”

Section: Radiation Treatment Protocolmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Wormhoudt

Boss

Lunn

et al. 2018

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

BackgroundConventional fractionated radiotherapy has been shown to be partially effective for management of pituitary tumors in cats that cause acromegaly and diabetes mellitus (DM), but, the efficacy and safety of stereotactic radiation therapy (SRT) as a treatment for acromegalic cats has not been described.HypothesisStereotactic radiation therapy is an effective and safe treatment for controlling acromegaly associated with pituitary adenomas in cats. Additionally, SRT‐treated acromegalic cats with DM will experience a decrease in insulin requirements after radiation therapy.AnimalsFifty‐three client‐owned cats referred to Colorado State University for SRT to treat pituitary tumors causing poorly controlled DM secondary to acromegaly.MethodsRetrospective study of cats treated for acromegaly with SRT between 2008 and 2016 at Colorado State University. Diagnosis of acromegaly was based on history, physical examination, laboratory results, and cross‐sectional imaging of the pituitary. Signalment, radiation protocol, insulin requirements over time, adverse effects, and survival were recorded.ResultsMedian survival time was 1072 days. Of the 41 cats for which insulin dosage information was available, 95% (39/41) experienced a decrease in required insulin dose, with 32% (13/41) achieving diabetic remission. Remission was permanent in 62% (8/13) and temporary in 38% (5/13) cats. Median duration to lowest insulin dose was 9.5 months. Of the treated cats, 14% developed hypothyroidism and required supplementation after SRT.ConclusionsStereotactic radiation therapy is safe and effective for treating cats with acromegaly. Cats treated with SRT have improved survival time and control of their DM when compared to previously reported patients treated with non‐SRT.

show abstract

Section: Radiation Treatment Protocolmentioning

confidence: 99%

“…Stereotactic radiation therapy is now an accepted treatment for many tumor types and locations in both human and veterinary medicine . Stereotactic radiation therapy delivers an ablative dose of radiation to the tumor while avoiding normal tissues in the field .…”

Section: Introductionmentioning

confidence: 99%

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Wormhoudt

Boss

Lunn

et al. 2018

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although chemotherapy has been used with some intracranial tumors, a survival benefit has not clearly been demonstrated, including for pituitary masses . The potential benefits of stereotactic radiotherapy for a variety of intracranial tumor types in dogs have previously been described, but pituitary tumors have accounted for very few stereotactic radiotherapy patients in the literature …”

Section: Introductionmentioning

confidence: 99%

Long‐term survival with stereotactic radiotherapy for imaging‐diagnosed pituitary tumors in dogs

Hansen

Zwingenberger

Théon

et al. 2018

Vet Radiology Ultrasound

View full text Add to dashboard Cite

Published studies on the use of stereotactic radiotherapy for dogs with pituitary tumors are limited. This retrospective observational study describes results of stereotactic radiotherapy for 45 dogs with imaging-diagnosed pituitary tumors. All dogs were treated at a single hospital during the period of December 2009-2015. The stereotactic radiotherapy was delivered in one 15 Gray (Gy) fraction or in three 8 Gy fractions. At the time of analysis, 41 dogs were deceased.Four were alive and censored from all survival analyses; one dog received 8 Gy every other day and was removed from protocol analyses. The median overall survival from first treatment was 311 days (95% confidence interval 226-410 days [range 1-2134 days]). Thirty-two dogs received 15 Gy (median overall survival 311 days; 95% confidence interval [range 221-427 days]), and 12 received 24 Gy on three consecutive days (median overall survival 245 days, 95% confidence interval [range 2-626 days]). Twenty-nine dogs had hyperadrenocorticism (median overall survival 245 days), while 16 had nonfunctional masses (median overall survival 626 days). Clinical improvement was reported in 37/45 cases. Presumptive signs of acute adverse effects within 4 months of stereotactic radiotherapy were noted in 10/45, and most had improvement spontaneously or with steroids. Late effects versus tumor progression were not discernable, but posttreatment blindness (2), hypernatremia (2), and progressive neurological signs (31) were reported.There was no statistical difference in median overall survival for different protocols. Patients with nonfunctional masses had longer median overall survival than those with hyperadrenocorticism (P = 0.0003). Survival outcomes with stereotactic radiotherapy were shorter than those previously reported with definitive radiation, especially for dogs with hyperadrenocorticism. K E Y W O R D SCushing's disease, hyperadrenocorticism, photon therapy, SRS, stereotaxis three-dimensional-conformal fields, or with a cone-based system for beam collimation. 17,18,25 There is one study of 51 dogs with

show abstract

“…The auditory tube is controlled by the tensor tympani and tensor veli palatini muscles innervated by the trigeminal nerve and the levator veli palatini and salpingopharyngeus muscles innervated by the vagus nerve. Trigeminal nerve lesions therefore also have been associated with auditory tube dysfunction and middle ear effusion in dogs . These neoplasms typically affect older dogs and are considered progressive .…”

Section: Introductionmentioning

confidence: 99%

“…Trigeminal nerve lesions therefore also have been associated with auditory tube dysfunction and middle ear effusion in dogs . These neoplasms typically affect older dogs and are considered progressive . Other differential diagnoses for unilateral MM atrophy include neuropathies such as trigeminal neuritis, idiopathic trigeminal neuropathy, and also could include myopathies, traumatic injury, or extension of other extra‐axial mass lesions .…”

Section: Introductionmentioning

confidence: 99%

Clinical findings and outcome of dogs with unilateral masticatory muscle atrophy

Milodowski

Amengual-Batle

Beltrán

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Little is known about the spectrum of underlying disorders in dogs with unilateral masticatory muscle (MM) atrophy. Objectives To evaluate the clinical presentation, magnetic resonance imaging (MRI) findings, and outcome of dogs with unilateral MM atrophy. Animals Sixty‐three client‐owned dogs. Methods The medical database was retrospectively reviewed for dogs that underwent MRI for evaluation of unilateral MM atrophy. Imaging studies were reviewed and follow‐up information was obtained from telephone interviews. Results Presumptive trigeminal nerve sheath tumor (pTNST) was diagnosed in 30 dogs (47.6%); survival time varied from 1 day to 21 months (median, 5 months). Other extra‐axial mass lesions were observed in 13 dogs (20.6%); survival time varied from 6 days to 25 months (median, 2.5 months). In 18 dogs (28.6%), no abnormalities were observed on MRI; neurological signs only progressed in 1 dog. Diagnosis had a significant influence on the type of neurological abnormalities, with additional neurological deficits observed in most dogs with pTNST and in all dogs with other extra‐axial mass lesions. Diagnosis had a significant effect on euthanasia at the time of diagnosis and likelihood of neurological deterioration. Dogs with mass lesions were more likely to be euthanized or experience neurological deterioration, whereas these outcomes occurred less often in dogs in which no causative lesion could be identified. Conclusions and Clinical Importance Trigeminal nerve sheath tumors should not be considered the only cause of unilateral MM atrophy. Our results illustrate the importance of performing a neurological examination and MRI when evaluating dogs with unilateral MM atrophy.

show abstract

Clinical and imaging findings, treatments, and outcomes in 27 dogs with imaging diagnosed trigeminal nerve sheath tumors: A multi‐center study

Cited by 25 publications

References 18 publications

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

Long‐term survival with stereotactic radiotherapy for imaging‐diagnosed pituitary tumors in dogs

Clinical findings and outcome of dogs with unilateral masticatory muscle atrophy

Contact Info

Product

Resources

About